← Back to Search

Anti-hypertensive

A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension

Phase 2
Waitlist Available
Research Sponsored by Ionis Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial is testing ION904, a new medication, to see if it can help lower blood pressure in people whose high blood pressure isn't well controlled by their current treatments. The study focuses on participants with mild to moderate hypertension. ION904 works by reducing a protein in the blood that can increase blood pressure.

Eligible Conditions
  • High Blood Pressure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ION904Experimental Treatment1 Intervention
Up to 4 monthly doses of ION904 will be administered by subcutaneous (SC) injection.
Group II: PlaceboPlacebo Group1 Intervention
Up to 4 monthly doses of placebo will be administered by SC injection.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ION904
2022
Completed Phase 2
~90

Find a Location

Who is running the clinical trial?

Ionis Pharmaceuticals, Inc.Lead Sponsor
150 Previous Clinical Trials
27,714 Total Patients Enrolled
~13 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top